Previous Close | 191.58 |
Open | 192.81 |
Bid | 191.03 x 100 |
Ask | 191.46 x 100 |
Day's Range | 188.51 - 193.04 |
52 Week Range | 126.97 - 213.83 |
Volume | |
Avg. Volume | 269,400 |
Market Cap | 21.018B |
Beta (5Y Monthly) | 0.61 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -4.94 |
Earnings Date | Nov 07, 2024 - Nov 14, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 273.43 |
The consensus price target hints at a 27.8% upside potential for BeiGene (BGNE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
As the major U.S. stock indexes edged higher recently, investors are keeping a close eye on significant earnings reports and economic indicators that could influence market sentiment. Amid this cautious optimism, identifying undervalued stocks can be crucial for those looking to capitalize on potential discounts in the current market landscape.
SAN MATEO, Calif., August 28, 2024--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on September 5, 2024, with a fireside chat at 10 a.m. EDT.